Bronchosol is a traditional medicinal product in the form of syrup used in cough and impeded expectoration. The active ingredients that it contains include extracts from the herb of thyme, the root of primrose and thymol. It is recommended in disorders of the respiratory tract when expectoration is impeded and secretion of liquid mucus in bronchi is insufficient. Antimicrobial activity of the components of Bronchosol, especially thyme and thymol, has frequently been reported in the literature. To date, there have not been any studies to confirm such activity of Bronchosol, though. The results of our research are the first one to point to the great activity of Bronchosol against microorganisms causing infections of the respiratory tract. It has been demonstrated that this product displayed antimicrobial activity against reference strains as well as strains of anaerobic and aerobic bacteria and fungi isolated from patients. The confirmation of the antimicrobial activity of Bronchosol provides an explanation of its effectiveness in the therapy of the respiratory tract infections.
ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Krzysiek J, Lesiak A, Szybka M, et al. The role of heterodimer IL 17A/F in atopic dermatitis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2022;39(6):1093-1100. doi:10.5114/ada.2022.122604. APA Krzysiek, J., Lesiak, A., Szybka, M., Michalak, A., Pastuszak-Lewandoska, D., & Grzegorczyk, J. et al. (2022). The role of heterodimer IL 17A/F in atopic dermatitis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 39(6), 1093-1100. https://doi.org/10.5114/ada.2022.122604 Chicago Krzysiek, Joanna, Aleksandra Lesiak, Małgorzata Szybka, Anna Michalak, Dorota Pastuszak-Lewandoska, Janina Grzegorczyk, and Magdalena Ciążyńska et al. 2022. "The role of heterodimer IL 17A/F in atopic dermatitis". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 39 (6): 1093-1100. doi:10.5114/ada.2022.122604. Harvard Krzysiek, J., Lesiak, A., Szybka, M., Michalak, A., Pastuszak-Lewandoska, D., Grzegorczyk, J., Ciążyńska, M., and Narbutt, J. (2022). The role of heterodimer IL 17A/F in atopic dermatitis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 39(6), pp.1093-1100. https://doi.org/10.5114/ada.2022.122604 MLA Krzysiek, Joanna et al. "The role of heterodimer IL 17A/F in atopic dermatitis." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 39, no. 6, 2022, pp. 1093-1100. doi:10.5114/ada.2022.122604. Vancouver Krzysiek J, Lesiak A, Szybka M, Michalak A, Pastuszak-Lewandoska D, Grzegorczyk J et al. The role of heterodimer IL 17A/F in atopic dermatitis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2022;39(6):1093-1100. doi:10.5114/ada.2022.122604.
Prostate cancer is one of the most common cancers in men, therefore has become recently an essential problem of public health. The factors influencing cancer include: androgens metabolism disorders, diabetes mellitus, overweight and obesity, smoking, alcohol and black coffee intake, diet rich in saturated fats and poor in unsaturated, lack of physical activity, geographical zone, race, such carcinogenic substances as: cadmium, materials used in rubber, painting, printing, ship industry etc., contagious factors and also older age and a positive family history of the disease. To diagnose prostate cancer in its early stage such screening procedures as physical examination--digital rectal exam (DRE) and determination of prostate-specific antigen (PSA) level in blood serum are used. The aim of the study was to assess prostate cancer risk factors occurrence in the examined 193 men, aged 50-70 years, who reported to urology outpatient department at Clinical Hospital in Lublin, measure the PSA level in blood serum and examine the correlation between them. Respondents filled in a questionnaire about the presence of prostate cancer risk factors and urogenital symptoms. The questionnaire was completed with DRE and PSA measurement. The results led us to the following conclusions: 1/ in the studied population elevated PSA level is determined in 3.1% of 193 examined men, 2/ increased PSA occurs mainly in men from rural areas, with elementary education, divorced, older (>60 years), using fat-rich diet, smokers, black coffee drinkers, with overweight or obesity and non diabetic, 3/ a combination of PSA test with DRE seems to be useful and rather cheap for the detection of prostate cancer in the early stage of its development.
Urological problems especially connected with prostate diseases appear in older men: prostatitis, benign prostatic hyperplasia, prostate cancer and others. Prostate cancer is the most common cancer in men and the second leading cause of deaths in male population. Therefore, it seems important to early detect prostate cancer in general practice setting due to screening procedures such as digital rectal exam and prostate-specific-antigen test. The aim of the study was to examine the character of diagnoses of a prostate disease among 1,004 men of the Lublin district who reported to a doctor during screening procedure carried out in urology outpatient clinic at Clinical Hospital in Lublin in the year 2000. After physical examination urologists initially diagnosed a prostate disease and sent men suspected to have a prostate cancer to further investigations. There was studied age and place of living. Benign prostate hyperplasia was the most common diagnosis made in 77.1% of subjects. It occurred most often in men aged 51-70 years. Prostate cancer was suspected in 3.5% of subjects. Frequency of benign prostate hyperplasia and prostate cancer suspicion increased with age. On the basis of studies screening procedures seem beneficial in the early detection of prostate cancer in men over 50.
Introduction. The mouthwash Dentofresh® produced by Phytopharm Kleka SA, intended for adults and children over the age of 6, is a prophylactic preparation. Using the mouthwash after having brushed the teeth has a preventive and healing influence on the hard tissues of teeth and gingiva. The mouthwash contains: eucalyptus, mint, thyme and sage oils, which show anti-inflammatory and antimicrobial activity. Aim. The aim of the study was to evaluate the effectiveness of Dentofresh® against strains of yeast-like fungi from the genus Candida. Material and methods. The study was conducted on 15 strains of yeast-like fungi from the genus Candida isolated from infections, and five reference strains. The fungicidal activity of the preparation (MFC – Minimal Fungicidal Concentration) against the strains of yeast-like fungi at the concentration recommended by its producer was evaluated. Results. Dentofresh® exhibited great fungicidal activity at the concentration recommended by the producer as quickly as 15 minutes after it was applied (against 87% of the strains), while after 30 minutes, all the tested strains of yeast-like fungi were destroyed. Conclusions. The preparation was effective against the genera of yeast-like fungi which are usually resistant to common antifungal medicines.
Abstract Background Vedolizumab (VDZ) is a gut-selective anti-lymphocyte trafficking drug, used to treat ulcerative colitis (UC) and Crohn’s disease (CD), lifelong conditions with unknown aetiology with frequent relapses and remitting course which are a burden for patients and a challenge for health care systems. We aimed to evaluate the real-world effectiveness of VDZ induction therapy for Polish patients with CD. Methods This was a multicenter, observational, prospective study involving patients with moderately to severely active CD qualified for reimbursed treatment with VDZ in 10 Polish centers between Apr 2020 and Nov 2021. The primary endpoints were clinical response (≥ 70-point reduction in Crohn's Disease Activity Index, CDAI) and remission rate (CDAI ≤ 150) at week 14. Other endpoints included changes from baseline (week 0, first dose of VDZ) to week 14 for patient-reported outcomes (PROs): quality of life (Inflammatory Bowel Disease Questionnaire, IBDQ), fatigue (Inflammatory Bowel Disease-Fatigue Self-assessment Scale, IBD-F), stool frequency (SF score) and abdominal pain score (APS). Results A total of 98 patients with CD were enrolled in the study. At baseline, the most common disease location in the cohort was ileocolonic CD (n=70/98, 72.9%). Fifty patients (51%) were on corticosteroids at week 0. Nine patients discontinued VDZ therapy before or at week 14, mainly due to lack of response (n=6/9, 66.7%). At week 14, 63.3% of patients (n=62/98) achieved clinical remission and 30% (n=15/50) steroid-free remission. Clinical response rate in overall study population was 90.8% (n=89/98). Median CDAI score decreased from 336.5 to 108.0 (p<0.001) at week 14 (Fig. 1). Declines from baseline were also observed in median CDAI sub-scores: SF score (38.0 vs 10.0; p<0.001) and APS (18.0 vs 2.0; p<0.001) (Fig. 1). At week 14, median changes from baseline scores on the IBDQ (total and all subscales) were statistically significant (p<0.001) (Fig. 2). Improvement was also observed after the VDZ 14-week treatment period in fatigue severity and frequency (p<0.01) as well as its impact on daily activities (p<0.001) based on IBD-F (Fig. 3). The percentage of patients without concomitant corticosteroids increased more than 1.5-fold from week 0 (49.0%) to week 14 (76.3%). Conclusion VDZ is effective in induction therapy and has significant impact on disease activity and Health-Related Quality of Life (HRQL) including fatigue in patients with CD.
